Plain-English translation of NCT07145229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called ABP-745 to see if it can help people who are having a sudden, painful gout attack. Researchers will compare ABP-745 at two different doses against the standard gout treatment () and a placebo to find out if the medication works better at relieving pain and swelling.
Gout attacks are sudden, severe inflammatory episodes that can be very painful and disabling. This medication is being tested because researchers believe it may reduce pain and swelling more effectively than current options for people experiencing acute gout.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to take one of three treatments: ABP-745 at a lower dose, ABP-745 at a higher dose, (the standard treatment), or a placebo. Neither you nor the researchers will know which treatment you're receiving. Your main job will be to track your pain levels and report any side effects; researchers will measure how well the medication reduces your pain and swelling compared to the other treatments.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States